Ellen 't Hoen LLM, PhD
Ellen 't Hoen LLM, PhD
Medicines Law & Policy
Verified email at medicineslawandpolicy.net - Homepage
Cited by
Cited by
25 years of the WHO essential medicines lists: progress and challenges
R Laing, B Waning, A Gray, N Ford, E Hoen
The Lancet 361 (9370), 1723-1729, 2003
TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha
E t Hoen
Chi. J. Int'l L. 3, 27, 2002
Essential medicines for universal health coverage
VJ Wirtz, HV Hogerzeil, AL Gray, M Bigdeli, CP de Joncheere, MA Ewen, ...
The Lancet 389 (10067), 403-476, 2017
Driving a decade of change: HIV/AIDS, patents and access to medicines for all
J Berger, A Calmy, S Moon
Journal of the International AIDS Society 14 (1), 1-12, 2011
The global politics of pharmaceutical monopoly power: drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and public health
EFM t Hoen
DiemenAMB, 2009
Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system?
S Moon, J Bermudez, E 't Hoen
PLoS medicine 9 (5), e1001218, 2012
Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review
N Ford, Z Shubber, P Saranchuk, S Pathai, N Durier, DP O'Brien, EJ Mills, ...
Clinical infectious diseases 57 (9), 1351-1361, 2013
A quiet revolution in global public health: The World Health Organization’s Prequalification of Medicines Programme
E FM‘t Hoen, HV Hogerzeil, JD Quick, HB Sillo
Journal of public health policy 35 (2), 137-161, 2014
The UNITAID patent pool initiative: bringing patents together for the common good
J Bermudez, E Hoen
The open AIDS journal 4, 37, 2010
Direct-to-consumer advertising: for better profits or for better health?
E Hoen
American Journal of Health-System Pharmacy 55 (6), 594-597, 1998
Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016
E FM‘t Hoen, J Veraldi, B Toebes, HV Hogerzeil
Bulletin of the World Health Organization 96 (3), 185, 2018
Harmful human use of donated veterinary drug
E Hoen, C Hodgkin, D Milkevicius
The Lancet 342 (8866), 308-309, 1993
Essential medicines are still essential
AL Gray, VJ Wirtz, E FM't Hoen, MR Reich, HV Hogerzeil
The Lancet 386 (10004), 1601-1603, 2015
Private patents and public health: changing intellectual property rules for access to medicines
E FM't Hoen
AMB Publishers, 2016
Access to Cancer Treatment: A study of medicine pricing issues with recommendations for improving access to cancer medication
E t Hoen
Oxfam International, 2015
Generic medicines are not substandard medicines
C Adelman, J Norris
The Lancet 359 (9314), 1351-1352, 2002
We urge WHO to act on cytomegalovirus retinitis
D Heiden, P Saranchuk, NN Tun, B Audoin, J Cohn, N Durier, G Holland, ...
The Lancet Global Health 2 (2), e76-e77, 2014
Global hepatitis C elimination: an investment framework
A Pedrana, J Howell, N Scott, S Schroeder, C Kuschel, JV Lazarus, ...
The Lancet Gastroenterology & Hepatology, 2020
Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation
E FM‘t Hoen, P Boulet, BK Baker
Journal of pharmaceutical policy and practice 10 (1), 1-9, 2017
Regulatory framework for access to safe, effective quality medicines
L Rägo, H Sillo, E Hoen, M Zweygarth
Antiviral therapy 19 (3_suppl), 69-77, 2014
The system can't perform the operation now. Try again later.
Articles 1–20